PARIS (Reuters) – French vaccines company Valneva said on Thursday that it was expanding trials on its ‘VLA2001’ COVID-19 vaccine candidate and remained in talks with the European Commission over a potential contract.
“Valneva continues discussions with the European Commission regarding a potential VLA2001 supply contract. The company is also actively pursuing opportunities to make VLA2001 available to other customers, subject to positive Cov-Compare data and regulatory approval,” it said in a statement.
(Reporting by Sudip Kar-Gupta; Editing by Jacqueline Wong)
